Hongming Pan Selected Research

Immunotherapy

3/2024	A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
7/2023	Efficacy and safety of PD‑1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: A multicenter retrospective study.
1/2023	An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor.
1/2023	Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature.
10/2022	Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.
9/2022	Composition of the Gut Microbiota Associated with the Response to Immunotherapy in Advanced Cancer Patients: A Chinese Real-World Pilot Study.
1/2022	Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors.
1/2022	Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy.
3/2021	Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
12/2020	Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hongming Pan Research Topics

Disease

83	Neoplasms (Cancer) 05/2024 - 09/2010
25	Colorectal Neoplasms (Colorectal Cancer) 09/2023 - 07/2013
24	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2011
19	Neoplasm Metastasis (Metastasis) 04/2024 - 01/2013
18	Hepatocellular Carcinoma (Hepatoma) 02/2024 - 01/2009
14	Stomach Neoplasms (Stomach Cancer) 02/2024 - 01/2015
13	Disease Progression 04/2024 - 04/2014
13	Lung Neoplasms (Lung Cancer) 12/2021 - 01/2005
12	Carcinogenesis 08/2021 - 01/2013
10	Breast Neoplasms (Breast Cancer) 12/2023 - 03/2014
9	Adenocarcinoma 12/2023 - 01/2015
9	Hypertension (High Blood Pressure) 12/2021 - 06/2015
5	Melanoma (Melanoma, Malignant) 03/2024 - 06/2019
4	Ovarian Neoplasms (Ovarian Cancer) 05/2024 - 03/2020
4	Anemia 12/2023 - 01/2020
4	Colonic Neoplasms (Colon Cancer) 02/2021 - 04/2014
3	Pancreatic Neoplasms (Pancreatic Cancer) 11/2023 - 12/2017
3	Colitis-Associated Neoplasms 09/2023 - 01/2020
3	Triple Negative Breast Neoplasms 01/2023 - 05/2015
3	Cancer Pain 02/2021 - 01/2007
3	Pain (Aches) 02/2021 - 01/2007
3	Diarrhea 03/2020 - 01/2016
3	Exanthema (Rash) 03/2020 - 06/2015
3	Fatigue 01/2016 - 01/2007
2	Liver Neoplasms (Liver Cancer) 02/2023 - 05/2021
2	Thrombocytopenia (Thrombopenia) 01/2023 - 01/2017
2	Febrile Neutropenia 01/2023 - 12/2021
2	Inflammation (Inflammations) 11/2022 - 06/2021
2	Lymphoma (Lymphomas) 08/2022 - 01/2019
2	Colitis 01/2022 - 01/2016
2	Cachexia 01/2019 - 01/2019

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 05/2024 - 01/2005
12	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2018
11	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2011
8	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2011
7	Bevacizumab (Avastin)FDA Link 01/2024 - 01/2015
7	Proteins (Proteins, Gene)FDA Link 09/2023 - 07/2013
7	HMPL-013IBA 01/2022 - 01/2017
7	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 01/2009
6	PlatinumIBA 05/2024 - 07/2013
6	MicroRNAs (MicroRNA)IBA 09/2023 - 01/2015
6	Monoclonal AntibodiesIBA 02/2023 - 08/2015
6	Fluorouracil (Carac)FDA LinkGeneric 02/2021 - 01/2014
6	Gefitinib (Iressa)FDA Link 11/2020 - 01/2011
5	Programmed Cell Death 1 ReceptorIBA 01/2024 - 01/2020
5	Gemcitabine FDA Link 11/2023 - 07/2013
4	tislelizumabIBA 01/2024 - 01/2020
4	pembrolizumabIBA 01/2024 - 06/2019
4	Phosphotransferases (Kinase)IBA 09/2023 - 01/2012
4	B7-H1 AntigenIBA 01/2023 - 11/2017
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 08/2020 - 07/2012
4	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 07/2013
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 01/2011
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2024 - 01/2021
3	atezolizumabIBA 04/2024 - 01/2021
3	CytokinesIBA 04/2024 - 01/2020
3	tepotinibIBA 02/2024 - 11/2020
3	Metformin (Glucophage)FDA LinkGeneric 12/2023 - 01/2014
3	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2023 - 01/2016
3	Dextrans (Dextran)FDA Link 09/2023 - 01/2016
3	AzoxymethaneIBA 09/2023 - 01/2016
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 09/2023 - 01/2016
3	apatinibIBA 01/2023 - 01/2021
3	CrizotinibIBA 01/2023 - 11/2015
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2022 - 07/2012
3	Peptides (Polypeptides)IBA 01/2022 - 09/2010
3	Paclitaxel (Taxol)FDA LinkGeneric 12/2021 - 07/2015
3	Long Noncoding RNAIBA 08/2021 - 05/2021
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 07/2013
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 01/2016
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 11/2020 - 01/2016
3	linifanibIBA 10/2020 - 10/2014
3	Small Interfering RNA (siRNA)IBA 09/2020 - 04/2014
3	LigandsIBA 09/2020 - 08/2015
3	Capecitabine (Xeloda)FDA Link 08/2020 - 01/2015
3	Alanine Transaminase (SGPT)IBA 08/2020 - 07/2012
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2020 - 08/2018
3	Estrogen ReceptorsIBA 01/2020 - 05/2015
3	Antineoplastic Agents (Antineoplastics)IBA 11/2015 - 01/2011
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 05/2024 - 01/2023
2	sitravatinibIBA 01/2024 - 01/2023
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 09/2023 - 07/2013
2	Beclin-1IBA 09/2023 - 04/2014
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 09/2023 - 01/2016
2	Dextran SulfateIBA 09/2023 - 06/2022
2	InterferonsIBA 02/2023 - 09/2010
2	Histone Deacetylase InhibitorsIBA 01/2022 - 08/2013
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 08/2013
2	EnzymesIBA 01/2022 - 03/2020
2	Analgesics (Analgesic Drugs)IBA 02/2021 - 01/2007
2	CalciumIBA 01/2021 - 03/2016
2	anlotinibIBA 01/2021 - 01/2020
2	regorafenibIBA 08/2020 - 06/2015
2	Oxycodone (Oxycontin)FDA LinkGeneric 06/2019 - 01/2007
2	TabletsIBA 06/2019 - 01/2007

Therapy/Procedure

55	Therapeutics 05/2024 - 01/2009
34	Drug Therapy (Chemotherapy) 05/2024 - 02/2013
14	Immunotherapy 03/2024 - 04/2016
3	Radiofrequency Ablation 01/2022 - 01/2016
3	Radiotherapy 02/2021 - 01/2018